Liquidia (NASDAQ:LQDA) CFO Sells $1,382,364.76 in Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 36,932 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer owned 350,919 shares in the company, valued at approximately $13,134,898.17. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 1st, Michael Kaseta sold 1,166 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total transaction of $37,533.54.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $38.79 on Friday. The company has a market capitalization of $3.37 billion, a PE ratio of -26.94, a PEG ratio of 0.68 and a beta of 0.48. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The stock’s 50 day moving average price is $32.68 and its 200-day moving average price is $25.77. Liquidia Corporation has a twelve month low of $11.26 and a twelve month high of $41.57.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. Liquidia’s revenue was up 1106.7% compared to the same quarter last year. On average, equities analysts anticipate that Liquidia Corporation will post -1.51 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its position in shares of Liquidia by 46.7% during the fourth quarter. SG Americas Securities LLC now owns 54,696 shares of the company’s stock valued at $1,886,000 after buying an additional 17,407 shares during the period. Insight Wealth Strategies LLC bought a new position in shares of Liquidia in the fourth quarter valued at approximately $4,891,000. Tudor Investment Corp ET AL purchased a new position in Liquidia during the third quarter valued at approximately $1,536,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the 3rd quarter worth approximately $34,000. Finally, Caxton Associates LLP purchased a new stake in Liquidia in the 3rd quarter worth approximately $389,000. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LQDA. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Wells Fargo & Company started coverage on Liquidia in a report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective for the company. Raymond James Financial restated a “strong-buy” rating and issued a $47.00 target price on shares of Liquidia in a research note on Tuesday, November 4th. Finally, HC Wainwright increased their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).